Navigation Links
Patients with heart failure need specialist care
Date:11/1/2013

New research from Karolinska Institutet in Sweden shows that patients with heart failure have high mortality and often are undertreated. According to a study, published in the scientific periodical JACC, many more of these patients would benefit from advanced treatment by heart specialists something that could be decided by a simple evaluation of five common risk factors for early death due to heart failure.

Heart failure affects 2-3% of the overall population and over 10% of the elderly worldwide, and is associated with high risk for early death and reduced quality of life. Drug therapy improves symptoms and reduces mortality and is well used. However, modern heart failure pacemakers, heart pumps and also heart transplantation are of great benefit in selected patients, but are poorly utilized. Earlier studies have shown that, a major reason is that heart failure patients are generally cared for by generalist doctors with limited awareness of these treatments.

In the present study, a team comprising researchers at Sweden's Karolinska Institutet, Linkping University, Stockholm South General Hospital and Karolinska University Hospital analysed data from 10,000 patients from the large Swedish Heart Failure Registry. First researchers showed that early death in these patients was related to heart failure (rather than for example age) suggesting that better treatment for heart failure would reduce mortality.

Second, the researchers defined 5 risk factors for mortality: poor pump capacity, poor kidney function, low blood count and absent treatment with the drugs ACE inhibitors and beta blockers. If any one of these risk factors was present in a given patient, the mortality was so high that the patient would potentially benefit from a heart failure pacemaker, heart pump and heart transplantation. This risk persisted after adjustment for a large number of other factors, such as patients' age, general health and other factors.

"Currently, less than 5% of patients with heart failure receive heart failure pacemakers and many fewer receive heart pumps or transplantation. Our findings suggest that many more need these treatments and should be referred to heart failure specialists for evaluation", says study leader Dr Lars H. Lund of Karolinska Institutet.

Karolinska Institutet and Stockholm County Council have initiated the cooperative "Project 4D", aiming to improve knowledge building within healthcare and research regarding four diagnoses, among them heart failure. The current study was financed by the Swedish Heart-Lung Foundation, the Stockholm County Council and the Swedish Association of Local Authorities and Regions.


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert  

Related medicine news :

1. New Report: The Online Experience of Sarcoma Patients and Supporters
2. Diet Doc Hormone Diets & Weight Loss Plans Reveal Healthy Weight Loss Treatments, Newly Enhanced by a Low Fat Diet, That Help Patients Reach Their Ideal Body Weight
3. Studies: Current hepatitis C treatments cant be used by more than half of patients; others lose opportunity for treatment
4. A Radiology Workflow Solution for Veterinarians and Their Animal Patients Launched
5. Fairfield CT Dentist Utilizes New Technology to Help Patients
6. New York, NY Gum Disease Patients can Now Receive Gentle Gum Disease Surgery with a Laser from Dr. Neda Azadivatan of Precision Periodontics & Dental Implants
7. Mount Sinai Oncologists Improve Quality of Care for Cancer Patients with Standardized Criteria for Palliative Care Consultation
8. Patients Can Avoid Complicated Procedures and Hemorrhoid Surgery with a Painless, 60-Second Procedure Now Offered by Dr. Cynthia Mullen
9. EyeCare 20/20, Short Hills Ophthalmology and the Laser Vision Center of New Jersey to Provide Cataract Surgery To 50 Patients this November
10. Chris Elliott Fund Hosts 2nd Annual Conference, Providing Hope to Brain Cancer and Brain Tumor Patients and Caregivers
11. Overlooked lymph nodes in rib cage have prognostic power for mesothelioma patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patients with heart failure need specialist care
(Date:9/25/2017)... ... September 25, 2017 , ... Ron ... an option to senior, upper-level executives speaking at a business luncheon today, "It ... high-level executive is an asset to be fully realized and activated by the ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a ... Reward” is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible ... we returned to our cars, my sister-in-law invited us to come over before the ...
(Date:9/25/2017)... September 25, 2017 - Orlando, FL, Microsoft Ignite Conference (PRWEB) , ... ... ... Hosts, Inc . announced today that they have teamed up to deliver Netmail’s Hadron ... on-demand service from a HIPAA/HITRUST compliant Azure Cloud. Netmail will be demo-ing their Hadron ...
(Date:9/25/2017)... ... ... Ash Borers kill Ash trees in as little as 1-3 years. The signs ... by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in ... signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
(Date:9/24/2017)... & Caicos Islands, BWI (PRWEB) , ... September 25, 2017 , ... ... to announce the resort is re-opening on October 1st. And, throughout the month ... three bedroom oceanfront rentals. , Hurricane Irma and Maria have passed and damage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: